Clinical Research

PreCardix^® is the result of over a decade research and development dedicated to finding an effective, sustainable and proven natural product to support blood pressure health.

Two clinical studies, Mare-study (preliminary clinical trial) and Marealis 13TBHM (peer-reviewed, double-blind, placebo-controlled, multicentre clinical trial), were conducted on the bioactive marine peptides (RSPC) in PreCardix^® between 2012 and 2015 on over two hundred and twenty male and female participants aged 30 – 75.

Clinical research found that the unique bioactive marine peptides derived from hydrolyzed shrimp shells (Pandalus Borealis) found in PreCardix^® have an ACE inhibiting mechanism of action. The use of bioactive marine peptides in clinical trials resulted in a statistically significant effect on blood pressure health in over 89% of participants within eight weeks or less.

Highlights of the Marealis 13TBHM study:

• 1,200 mg per day of unique bioactive marine peptides have a statistically significant effect on blood pressure health in adults with mild to moderate hypertension
• Angiotensin II levels were significantly reduced in the treatment group compared to baseline documenting the ACE-inhibiting action
• No serious adverse effects were reported by study participants, including hypotension, angioedema, dry cough, or hyperkalemia
• 89% of clinical trial participants experienced a significant effect on blood pressure health within eight weeks or less
• 43% of clinical trial participants experienced a change in blood pressure by over 10mmHg in eight weeks
• 24% of clinical trial participants experienced a change in blood pressure by over 15mmHg within eight weeks

For more information on PreCardix^® clinical indications, safety and effectiveness, please review the resources below, including clinical research, product monographs, and FAQs.

Important Information

Product Monograph